Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Burning Rock Starts Large Pan-Cancer Early Detection Study

publication date: May 19, 2021

Beijing's Burning Rock Biotech will start a large blood-based, pan-cancer early-detection study in China using a multi-omics approach. The trial will enroll 11,879 participants with 22 cancer types, which cause 88% of cancer incidence in China, along with healthy control individuals. The trial aims to make new discoveries that will improve early stage liquid biopsies. Burning Rock recently reported that its Elsa-seq early detection assay had a 80.6% sensitivity and 98.3% specificity in six major cancer types. More details....

Stock Symbol: (NSDQ: BNR)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.